# Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

> **NCT03829917** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fundacion Nacional de Dermatologia** · enrollment: 120 (actual)

## Conditions studied

- Cutaneous Leishmaniasis, American

## Interventions

- **DRUG:** Miltefosine and Paromomycin
- **DRUG:** miltefosine
- **DRUG:** paromomycin

## Key facts

- **NCT ID:** NCT03829917
- **Lead sponsor:** Fundacion Nacional de Dermatologia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-31
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829917, "Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03829917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*